Business

Bristol to Buy Drug Developer RayzeBio for $4.1 Billion

Published

3 years ago

on



Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline. Bloomberg’s Madison Mueller reports.

Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com
Connect with us on…
Twitter: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness/
Instagram: https://www.instagram.com/quicktake/?hl=en

source

Related Topics:

2 Comments

  1. @ayenewwolde4393

    January 1, 2024 at 8:07 am

    beaten down bios outperforming s&p

    Reply

  2. @nantanitinelapan6723

    January 1, 2024 at 8:07 am

    Thank you love so much

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version